+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Womens Health Diagnostics Market by Type and End User - Global Opportunities and Industry Forecasts, 2017-2023

  • ID: 4612791
  • Report
  • December 2017
  • Region: Global
  • 245 Pages
  • Allied Analytics LLP
The global women’s health diagnostics market was valued at $13,133 million in 2016, and is projected to reach $21,501 million in 2023 at a CAGR of 7.0% from 2017 to 2023. Women are more prone to obesity and reproduction related issues as compared to men. Women’s health diagnostics include screening, testing or diagnosing, and monitoring of several women-related disorders namely breast cancer, ovarian, cancer, cervical cancer, menopause, and pregnancy.



Rise in number of chronic and lifestyle disorders, which lead to various cancer such as breast cancer is the major factor that contributes to the growth of the women’s health diagnostics market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period. The global women’s health diagnostics market is segmented on the basis of type, end user, and region. By type, it is classified into diagnostic devices, diagnostic tests, and accessories and consumables. The diagnostic devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. Diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing includes tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings, diagnostic and imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. KEY BENEFITS FOR STAKEHOLDERS The study provides an in-depth analysis of the global women’s health diagnostics market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets. Comprehensive analysis of factors that drive and restrict the market growth is provided. Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided. Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market. KEY MARKET SEGMENTS By Type Diagnostic Devices Biopsy Devices Imaging and Monitoring System Ultrasound Devices OB/GYN Ultrasound Breast Ultrasound Mammography Systems Analog Mammography Digital Mammography Breast Tomosynthesis MRI Systems Nuclear Imaging Diagnostic Tests Breast Cancer Testing Hormone Receptor Test Immunohistochemistry (IHC) Test Other Tests Cervical Cancer Testing PAP Smear (PAP) Test HPV Test Prenatal Genetic Screening and Carrier Testing Cystic Fibrosis Other Diseases Pregnancy and Ovulation Testing Lab-based Pregnancy and Ovulation Testing Home Based Pregnancy and Ovulation Testing Ovarian Cancer Testing Accessories and Consumables By End User Hospitals and Clinics Home Care Settings Diagnostic and Imaging Centers Others By Region North America U.S. Canada Mexico Europe Germany France UK Italy Spain Rest of Europe Asia-Pacific Japan China Australia India South Korea Rest of Asia-Pacific LAMEA Brazil Saudi Arabia South Africa Rest of LAMEA LIST OF KEY PLAYERS PROFILED IN THE REPORT Abbott Laboratories Becton, Dickinson and Company Carestream Health F. Hoffmann-La Roche AG GE Healthcare Hologic, Inc. Koninklijke Philips N.V. Quest Diagnostics Inc. Siemens AG Cardinal Health LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request) Cook Medical Incorporated C. R. Bard, Inc. MedGyn Products, Inc. Thermo Fisher Scientific
Frequently Asked Questions about the Global Women’S Health Diagnostics Market

What is the estimated value of the Global Women’S Health Diagnostics Market?

The Global Women’S Health Diagnostics Market was estimated to be valued at $13133.0 million in 2016.

What is the growth rate of the Global Women’S Health Diagnostics Market?

The growth rate of the Global Women’S Health Diagnostics Market is 7.3%, with an estimated value of $21501.0 million by 2023.

What is the forecasted size of the Global Women’S Health Diagnostics Market?

The Global Women’S Health Diagnostics Market is estimated to be worth $21501.0 million by 2023.
Note: Product cover images may vary from those shown
CHAPTER 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS FOR STAKEHOLDERS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models CHAPTER 2 EXECUTIVE SUMMARY 2.1. KEY FINDINGS OF THE STUDY 2.2. CXO PERSPECTIVE CHAPTER 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.2.2.1. Top Winning Strategies, By Year, 2014-2017 3.2.2.2. Top Winning Strategies, By Development, 2014-2017 (%) 3.2.2.3. Top Winning Strategies, By Company, 2014-2017 3.3. MARKET DYNAMICS 3.3.1. Drivers 3.3.1.1. Growth in geriatric female population 3.3.1.2. Increasing incidence of various chronic and lifestyle disorders in women 3.3.1.3. Rise in demand for point-of-care diagnostic testing 3.3.1.4. High adoption of imaging procedures 3.3.2. Restrains 3.3.2.1. High cost of imaging and monitoring systems 3.3.2.2. Lack of skilled professionals 3.3.3. Opportunities 3.3.3.1. Miniaturization of ultrasound devices 3.3.3.2. Untapped emerging economies 3.3.4. Impact analysis CHAPTER 4 WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE 4.1. OVERVIEW 4.1.1. Market size and forecast 4.2. DIAGNOSTIC DEVICES 4.2.1. Key market trends, growth factors, and opportunities 4.2.2. Market size and forecast 4.2.3. Biopsy devices 4.2.3.1. Market size and forecast 4.2.4. Imaging and monitoring systems 4.2.4.1. Market size and forecast 4.2.4.2. Ultrasound imaging systems 4.2.4.2.1. Market size and forecast 4.2.4.2.2. OB/GYN ultrasound 4.2.4.2.2.1. Market size and forecast 4.2.4.2.3. Breast ultrasound 4.2.4.2.3.1. Market size and forecast 4.2.4.3. Mammography systems 4.2.4.3.1. Market size and forecast 4.2.4.3.2. Analog mammography systems 4.2.4.3.2.1. Market size and forecast 4.2.4.3.3. Digital mammography systems 4.2.4.3.3.1. Market size and forecast 4.2.4.3.4. Breast tomosynthesis 4.2.4.3.4.1. Market size and forecast 4.2.4.4. MRI systems 4.2.4.4.1. Market size and forecast 4.2.4.5. Nuclear imaging systems 4.2.4.5.1. Market size and forecast 4.3. DIAGNOSTIC TESTS 4.3.1. Key market trends, growth factors, and opportunities 4.3.2. Market size and forecast 4.3.3. Breast cancer testing 4.3.3.1. Market size and forecast 4.3.3.2. Hormone receptor test 4.3.3.2.1. Market size and forecast 4.3.3.3. Immunohistochemistry (IHC) test 4.3.3.3.1. Market size and forecast 4.3.3.4. Other breast cancer tests 4.3.3.4.1. Market size and forecast 4.3.4. Cervical cancer testing 4.3.4.1. Market size and forecast 4.3.4.2. PAP smear (PAP) test 4.3.4.2.1. Market size and forecast 4.3.4.3. HPV test 4.3.4.3.1. Market size and forecast 4.3.5. Prenatal genetic screening & carrier testing 4.3.5.1. Market size and forecast 4.3.5.2. Cystic fibrosis 4.3.5.2.1. Market size and forecast 4.3.5.3. Other diseases 4.3.5.3.1. Market size and forecast 4.3.6. Pregnancy & ovulation testing 4.3.6.1. Market size and forecast 4.3.6.2. Lab-based pregnancy & ovulation testing 4.3.6.2.1. Market size and forecast 4.3.6.3. Home-based pregnancy & ovulation testing 4.3.6.3.1. Market size and forecast 4.3.7. Ovarian cancer testing 4.3.7.1.1. Market size and forecast 4.4. ACCESSORIES & CONSUMABLES 4.4.1. Key market trends, growth factors, and opportunities 4.4.2. Market size and forecast CHAPTER 5 WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. HOSPITALS AND CLINICS 5.2.1. Market size and forecast 5.3. HOME CARE SETTING 5.3.1. Market size and forecast 5.4. DIAGNOSTICS & IMAGING CENTERS 5.4.1. Market size and forecast 5.5. OTHERS 5.5.1. Market size and forecast CHAPTER 6 WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION 6.1. OVERVIEW 6.1.1. Market size and forecast 6.2. NORTH AMERICA 6.2.1. Key market trends, growth factors, and opportunities 6.2.2. North America womens health diagnostics market, by country 6.2.2.1. Market size and forecast 6.2.3. U.S. 6.2.3.1. U.S. womens health diagnostics market 6.2.4. Canada 6.2.4.1. Canada womens health diagnostics market 6.2.5. Mexico 6.2.5.1. Mexico womens health diagnostics market 6.2.6. North America womens health diagnostics market, by type 6.2.7. North America womens health diagnostics market, by end user 6.3. EUROPE 6.3.1. Key market trends, growth factors, and opportunities 6.3.2. Europe womens health diagnostics market, by country 6.3.3. Market size and forecast 6.3.4. Germany 6.3.4.1. Germany womens health diagnostics market 6.3.5. France 6.3.5.1. France womens health diagnostics market 6.3.6. UK 6.3.6.1. UK womens health diagnostics market 6.3.7. Italy 6.3.7.1. Italy womens health diagnostics market 6.3.8. Spain 6.3.8.1. Spain womens health diagnostics market 6.3.9. Rest of Europe 6.3.9.1. Rest of Europe womens health diagnostics market 6.3.10. Europe womens health diagnostics market, by type 6.3.11. Europe womens health diagnostics market, by end user 6.4. ASIA-PACIFIC 6.4.1. Key market trends, growth factors, and opportunities 6.4.2. Asia-Pacific womens health diagnostics market, by country 6.4.2.1. Market size and forecast 6.4.3. China 6.4.3.1. China womens health diagnostics market 6.4.4. Japan 6.4.4.1. Japan womens health diagnostics market 6.4.5. India 6.4.5.1. India womens health diagnostics market 6.4.6. Australia 6.4.6.1. Australia womens health diagnostics market 6.4.7. South Korea 6.4.7.1. South Korea womens health diagnostics market 6.4.8. Rest of Asia-Pacific 6.4.8.1. Rest of Asia-Pacific womens health diagnostics market 6.4.9. Asia-Pacific womens health diagnostics market, by type 6.4.10. Asia-Pacific womens health diagnostics market, by end user 6.5. LAMEA 6.5.1. Key market trends, growth factors, and opportunities 6.5.2. LAMEA womens health diagnostics market, by country 6.5.3. Market size and forecast 6.5.4. Brazil 6.5.4.1. Brazil womens health diagnostics market 6.5.5. Saudi Arabia 6.5.5.1. Saudi Arabia womens health diagnostics market 6.5.6. South Africa 6.5.6.1. South Africa womens health diagnostics market 6.5.7. Rest of LAMEA 6.5.7.1. Rest of LAMEA womens health diagnostics market 6.5.8. LAMEA womens health diagnostics market, by type 6.5.9. LAMEA womens health diagnostics market, by end user CHAPTER 7 COMPANY PROFILES 7.1. ABBOTT LABORATORIES 7.1.1. Company overview 7.1.2. Company snapshot 7.1.3. Operating business segments 7.1.4. Business performance 7.1.5. Key strategic moves and developments 7.2. BECTON, DICKINSON AND COMPANY 7.2.1. Company overview 7.2.2. Company snapshot 7.2.3. Operating business segments 7.2.4. Product portfolio 7.2.5. Business performance 7.2.6. Key strategic moves and developments 7.3. CARDINAL HEALTH, INC. 7.3.1. Company overview 7.3.2. Company snapshot 7.3.3. Product portfolio 7.3.4. Operating business segments 7.3.5. Business performance 7.4. CARESTREAM HEALTH INC. 7.4.1. Company overview 7.4.2. Company snapshot 7.4.3. Operating business segments 7.4.4. Product portfolio 7.5. COOK MEDICAL 7.5.1. Company overview 7.5.2. Company snapshot 7.5.3. Operating business segments 7.5.4. Product portfolio 7.6. C. R. BARD INC. 7.6.1. Company overview 7.6.2. Company snapshot 7.6.3. Operating business segments 7.6.4. Product portfolio 7.6.5. Business performance 7.7. F. HOFFMANN-LA ROCHE LTD. 7.7.1. Company overview 7.7.2. Company snapshot 7.7.3. Operating business segments 7.7.4. Product portfolio 7.7.5. Business performance 7.7.6. Key strategic moves and developments 7.8. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY) 7.8.1. Company overview 7.8.2. Company snapshot 7.8.3. Operating business segments 7.8.4. Product portfolio 7.8.5. Business performance 7.8.6. Key strategic moves and developments 7.9. HOLOGIC, INC. 7.9.1. Company overview 7.9.2. Company snapshot 7.9.3. Operating business segments 7.9.4. Product portfolio 7.9.5. Business performance 7.9.6. Key strategic moves and developments 7.10. KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE) 7.10.1. Company overview 7.10.2. Company snapshot 7.10.3. Operating business segments 7.10.4. Product portfolio 7.10.5. Business performance 7.11. MEDGYN PRODUCTS, INC. 7.11.1. Company overview 7.11.2. Company snapshot 7.11.3. Operating business segments 7.11.4. Product portfolio 7.12. QUEST DIAGNOSTICS INCORPORATED. 7.12.1. Company overview 7.12.2. Company snapshot 7.12.3. Operating business segments 7.12.4. Product portfolio 7.12.5. Business performance 7.13. SIEMENS AKTIENGESELLSCHAFT 7.13.1. Company overview 7.13.2. Company snapshot 7.13.3. Operating business segments 7.13.4. Product portfolio 7.13.5. Business performance 7.13.6. Key strategic moves and developments 7.14. THERMO FISHER SCIENTIFIC, INC. 7.14.1. Company overview 7.14.2. Company snapshot 7.14.3. Operating business segments 7.14.4. Product portfolio 7.14.5. Business performance
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...